Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Change in Accured Expenses data on file, last reported at -$57.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$57.0 million, down 18.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (down 56.57% YoY), and the FY2025 annual result was $24.0 million, down 48.94% from the prior year.
• Change in Accured Expenses eased to -$57.0 million in Q1 2026 per RARE's latest filing, from $37.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $57.4 million in Q2 2022 and troughed at -$57.0 million in Q1 2026.
• A 5-year average of $5.5 million and a median of $11.2 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses soared 375.52% in 2022, then tumbled 140.02% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $27.4 million in 2022, then slumped by 44.49% to $15.2 million in 2023, then soared by 204.72% to $46.4 million in 2024, then fell by 20.22% to $37.0 million in 2025, then sank by 254.0% to -$57.0 million in 2026.
• Business Quant data shows RARE's Change in Accured Expenses at -$57.0 million in Q1 2026, $37.0 million in Q4 2025, and $45.1 million in Q3 2025.